# Aclaris Therapeutics (ACRS) — Overview

ACRS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/acrs

## Price

Last close $3.49 on Oct 15, 2026. 52-week range $1.81 – $6.54.

## Company profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $8.2M |
| Revenue (quarter) | $1.6M |
| Revenue growth (year over year) | -8.33% |
| Gross profit (trailing twelve months) | $6.3M |
| Gross margin | 76.08% |
| Net income (trailing twelve months) | −$75.7M |
| Net income (quarter) | −$21.5M |
| Net income growth (year over year) | -39.38% |
| Net margin | -921.50% |
| Return on equity | -59.10% |
| EPS (trailing twelve months) | −$0.58 |
| Book value per share | $0.89 |
| P/E (trailing twelve months) | — |
| Price to book | 4.1 |
| Debt to assets | 30.67% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is Aclaris Therapeutics (ACRS) profitable?

No. Aclaris Therapeutics reported a net loss of $75.7M over the trailing twelve months.

### How much revenue does Aclaris Therapeutics (ACRS) make?

Aclaris Therapeutics generated $8.2M in revenue over the trailing twelve months, down 8.33% year over year.

### How do I buy stock in Aclaris Therapeutics (ACRS)?

ACRS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).